RT Journal Article
SR Electronic
T1 Dynamics of antibody responses, cellular immunity, and breakthrough infections among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.29.22270052
DO 10.1101/2022.01.29.22270052
A1 Uwamino, Yoshifumi
A1 Kurafuji, Toshinobu
A1 Takato, Kumiko
A1 Sakai, Akiko
A1 Tanabe, Akiko
A1 Noguchi, Masayo
A1 Yatabe, Yoko
A1 Arai, Tomoko
A1 Ohno, Akemi
A1 Tomita, Yukari
A1 Shibata, Ayako
A1 Yokota, Hiromitsu
A1 Yamasawa, Wakako
A1 Namkoong, Ho
A1 Sato, Yasunori
A1 Hasegawa, Naoki
A1 Wakui, Masatoshi
A1 Murata, Mitsuru
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/01/30/2022.01.29.22270052.abstract
AB Introduction The waning of the antibody titre after the first two doses of the Pfizer-BioNTech BNT162b2 mRNA SARS-CoV-2 vaccine was reported. However, knowledge of the dynamics of cellular immunity is scarce. Here, we performed a prospective cohort study to disclose antibody and cellular immunity dynamics and discuss the relationship between immunity and breakthrough infection.Methods The study had a prospective cohort design. Antibody titres against SARS-CoV-2 in serially collected serum samples of 608 Japanese vaccinees after 6 months of vaccination were measured. Simultaneously, T-cell immunity dynamics were assessed using the QuantiFERON SARS-CoV-2 assay. Additionally, participants with suspected breakthrough infection were detected according to the positive conversion of the IgG assay for nucleocapsid proteins of SARS-CoV-2.Results Antibody titres were elevated 3 weeks after vaccination and waned over the remainder of the study period. The QuantiFERON SARS-CoV-2 assay performed on 536 participants demonstrated the similar dynamics. Six participants without predisposing medical conditions demonstrated positive conversion of the IgG assay for nucleocapsid proteins, while five were asymptomatic.Conclusion Waning of humoral and cellular immunity within 6 months of administration of two doses of BNT162b2 vaccine among Japanese healthcare professionals and the occurrence of asymptomatic breakthrough infection was suspected in approximately 1 of 100 vaccinees.(UMIN000043340)Competing Interest StatementYU, MW, and MM own patents for the STACIA SARS-CoV-2 Neutralization Antibody Test. The STACIA SARS-CoV-2 Neutralization Antibody Test, HISCL SARS-CoV-2 S-IgG/N-IgG Test, and QuantiFERON SARS-CoV-2 ELISA kit were partially provided free of charge by MBL Corporation, Sysmex Corporation, and Qiagen, respectively.Funding StatementThis study was funded by the Japan Agency for Medical Research and Development (Grant number: 21fk0108469h0001), the Research Funds of the Keio University School of Medicine, and a grant from the Public Foundation of the Vaccination Research Centre, Japan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the Keio University School of Medicine (approval no. 20200330).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors